This protocol is judged by an institutional assessment board, an impartial group that evaluations any clinical trials involving people. If a review requires a Schedule I drug, as soon as the board approves the protocol as ethical, the researchers really need to apply for an investigational new drug (IND) variety in the FDA.This article includes a l